PB-Cre/Pten/Smad4 mouse prostate cancer micorarray for CRPC and lung metastasis studies

PB-Cre/Pten/Smad4 is a transgenic mouse model of metastatic prostate adenocarcinoma (PMID: 21289624). To study the transcriptomic alterations associated with castration-resistant prostate cancer (CRPC), the PB-Cre/Pten/Smad4 males with established prostate cancer were treated with surgical castration followed by enzalutamide-admixed diet. After about 4 weeks, dorsolateral prostate (DLP) lobes of treatment-naïve prostate tumors (N=2) and CRPC tumors (N=3) were harvested and extracted for RNA purification and microarray profiling. To further study the transcriptomic changes associated with lung metastases of the PB-Cre/Pten/Smad4/mTmG CRPC model, the PB-Cre/Pten/Smad4 males with established prostate cancer were treated with surgical castration followed by enzalutamide-admixed diet. About 3 months later, from one mouse anterior prostate (AP), dorsolateral prostate (DLP), ventral prostate (VP) and GFP+ lung metastasis nodules were each harvested for RNA purification and microarray profiling. The samples were all harvested from PB-Cre/Pten/Smad4 male mice. For the study of CRPC, treatment-naïve prostate tumors (N=2) and CRPC tumors (N=3) were profiled. For the study of CRPC primary tumor and lung metastasis, 1 AP sample, 1 DLP sample, 1 VP sample and 1 lung metastasis sample were profiled, all from one mouse.